FDA Moves to Exclude Semaglutide, Tizerpatide, and Liraglutide from 503B Bulk Substances List Lengea RFK Jr. & claimed regenerative peptides like BPC 157 The Niche The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner